ERBB2 and gastric cancer: In addition, given that trastuzumab is an approved drug for treating HER2+ GC and PAM pathway activation has been described as a marker of resistance to anti-HER2 therapy in GC, any investigation of the potential of DIACC3010 as a GC treatment should also include combination with trastuzumab.